Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.43 |
| ▸ | PYGM | P11217 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827367 | 0.88 | TK1 (0.44) | TK1BLM | |
| SCHEMBL4364016 | 0.87 | ALDH1A1 (0.43) | TK1PYGMP2RY6KMT2A | |
| SCHEMBL9744721 | 0.87 | LMNA (0.43) | TK1P2RY6P2RY14 | |
| SCHEMBL8176114 | 0.86 | TK1 (0.33) | TK1 | |
| SCHEMBL8167928 | 0.85 | TK2 (0.37) | TK1 | |
| SCHEMBL9803727 | 0.83 | TK1 (0.36) | TK1 | |
| SCHEMBL4366634 | 0.81 | SLC28A1 (0.36) | P2RY6 | |
| SCHEMBL10590192 | 0.79 | TK1 (0.39) | TK1PYGMP2RY6P2RY14CYP1A2 | |
| SCHEMBL10736899 | 0.79 | TK1 (0.39) | TK1PYGMP2RY6P2RY14CYP1A2 | |
| SCHEMBL6656869 | 0.79 | TK1 (0.39) | TK1PYGMP2RY6P2RY14CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11246590-A | — | — | None | — | — | JP | disclosed |
| US-6967079-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| WO-2005065694-A1 | THERAPEUTIC COMPOSITION FOR THE TREATMENT OF HUMAN EYE ACCOMMODATION DISORDERS | ANBEN PHARMA (FR) | 2005-07-21 | — | — | WO | disclosed |
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | MATTEUCCI MARK D (US) | 2003-11-06 | — | — | US | disclosed |
| US-6617437-B1 | Modified oligonucleotide of given formula; useful in diagnostics and therapeutics | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| EP-0719272-B1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-6005096-A | FOR OLIGONUCLEOTIDES THAT ARE MODIFIED TO ENHANCE THE BINDING AFFINITY AND TO BEAR DETECTABLE LABELS; FOR DIAGNOSTIC USE | GILEAD SCIENCES, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| JP-H11246590-A | PRODUCTION OF TRIFLUOROMETHYLURACIL DERIVATIVE | ASAHI GLASS CO LTD | 1999-09-14 | — | — | JP | disclosed |
| US-5763588-A | Pyrimidine derivatives for labeled binding partners | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0719272-A1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5502177-A | POLYCYCLIC STRUCTURE BOUND TO OLIGONUCLEOTIDE, FLUORESCENT LABEL, IMMUNOASSAY | GILEAD SCIENCES, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| US-5434257-A | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages | GILEAD SCIENCES, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995011911-A1 | BINDING COMPETENT OLIGOMERS CONTAINING UNSATURATED 3',5' AND 2',5' LINKAGES | GLAXO WELLCOME INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| WO-1995007918-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | HNRNPH3, NSUN2, HNRNPH1 | TK1 24/4885PYGM 3089/4885P2RY6 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.